Melanotan II

Also known as: MT-II, MT-2

Evidence Tier Chigh riskadvancednot approved

Unlicensed broad melanocortin agonist with pigmentation and sexual side-effect profiles. Highest compliance risk.

FDA Safety Flag

The FDA has identified this substance as one that may present significant safety risks when used in compounding, including concerns about immunogenicity, impurity characterization, and/or insufficient safety information.

Not Approved

This substance is not approved by any major regulatory body for human therapeutic use. All information is derived from preclinical research, limited clinical studies, or off-label contexts.

High Compliance Risk

This substance carries the highest compliance risk for platforms, advertisers, and payment processors. Ad platforms, payment rails, and regulatory bodies actively scrutinize products in this category.

Overview

Melanotan II is a broad melanocortin receptor agonist. Human evidence is dominated by case reports and observational harms rather than controlled therapeutic trials. FDA compounding safety note explicitly cites serious adverse events including melanoma, posterior reversible encephalopathy syndrome, sympathomimetic toxidrome, and priapism. This compound has the highest fraud/overclaim density and compliance risk in the peptide market.

Research Details

Mechanism of Action

Broad melanocortin receptor agonist with pigment and sexual side-effect profiles. Bremelanotide (PT-141) is an active metabolite/derivative in this axis.

Study Dose Range

Not a mainstream clinical product; human evidence dominated by case reports.

Administration Routes

subcutaneous

Onset / Timeline

Pigmentation changes can occur quickly; adverse events can be acute.

Expected Effects

Pigmentation changes (tanning); sexual arousal effects. NOT a controlled therapeutic product.

Adverse Effects

FDA cites serious adverse events: melanoma, posterior reversible encephalopathy syndrome, sympathomimetic toxidrome, priapism. Immunogenicity/impurity concerns.

Contraindications

High risk across the board; unlicensed and unapproved.

Interaction Notes

Unknown; risk may increase with UV exposure behaviors and stimulant-like exposures.

Related Goals

Skin & HairSexual Health & Libido

Known Interactions

contraindicated with PT-141

Two melanocortin agonists; FDA reports serious adverse events for melanotan II; Rx bremelanotide has cardiovascular contraindications/warnings.

caution with Melanotan I

Melanocortin agonist overlap; conservative caution.

Available From

No vendors currently listed for this peptide.

Frequently Compared

Melanotan I

FDA-approved MC1R agonist (SCENESSE implant) for erythropoietic protoporphyria. Prescription only.

Tier A

PT-141

FDA-approved melanocortin agonist (Vyleesi) for HSDD in premenopausal women. Prescription only.

Tier A

Oxytocin

Well-studied neuropeptide with extensive human research on social/emotional processing. Prescription product.

Tier A

Kisspeptin

Upstream regulator of reproductive axis (GnRH/LH/FSH). FDA-flagged for compounding concerns.

Tier B

Information provided for educational and research reference only. Not medical advice. Not for diagnosing, treating, curing, or preventing disease. Products referenced are labeled Research Use Only (RUO) by vendors; not for human or veterinary use.